Toward a universal inhibitor of retroviral proteases: Comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV

Protein Science

Volumn 7, Issue 11, 1998, Pages 2314-2323

  Kervinen, Jukka ^a   Lubkowski, Jacek ^a   Zdanov, Alexander ^a   Bhatt, Deepa ^b   Dunn, Ben M ^b   Hui, Kwan Y ^c   Powell, David J ^d   Kay, John ^d   Wlodawer, Alexander ^a   Gustchina, Alla ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Drug design; Drug resistance; HIV; Proteases; Retroviruses

Indexed keywords

ANTIRETROVIRUS AGENT; ASPARTIC PROTEINASE; LP 130; PROTEINASE INHIBITOR; STATINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; EQUINE INFECTIOUS ANEMIA VIRUS; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; RETROVIRUS; VIRUS RESISTANCE;

ANIMALIA; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 0031765908     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560071108     Document Type: Article

References (39)

1. Brünger A. 1992. X-PLOR version 3.1: A system for X-ray crystallography and NMR. New Haven: Yale University Press.
2. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires KE, Deutsch PJ, Emini EA. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-511.
3. Dunn BM, Gustchina A, Wlodawer A, Kay J. 1994. Subsite preferences of retroviral proteinases. Methods Enzymol 241:254-218.
4. Erickson J, Neidhart DJ, VanDrie J, Kempf DJ, Wang XC, Norbeck DW, Planner JJ, Rittenhouse JW, Turon M, Wideburg N, Kohlbrenner WE, Simmer R, Helfrich R, Paul DA, Knigge M. 1990. Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 249:527-533.
5. Erickson JW, Burt SK. 1996. Structural mechanisms of HIV drug resistance. Annu Rev Pharmacol Toxicol 36:545-571.
6. Garry RF, Krieg AM, Cheevers WP, Montelaro RC, Golding H, Fermin CD, Gallaher WR, 1995. Retroviruses and their roles in chronic inflammatory diseases and autoimmunity. In: Levy JA, ed. The retroviridae. New York: Plenum Press. pp 491-603.
7. Gulnik SV, Suvorov LI, Liu B, Yu B, Anderson B, Mitsuya H, Erickson JW. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34:9282-9287.
8. Gustchina A, Kervinen J, Powell DJ, Zdanov A, Kay J, Wlodawer A. 1996. Structure of equine infectious anemia virus proteinase complexed with an inhibitor. Protein Sci 5:1453-1465.
9. Gustchina A, Weber IT. 1991. Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins Struct Fund Genet J 10:325-339.
10. Hendrickson WA. 1985. Stereochemically restrained refinement of macromolecular structures. Methods Enzymol 115:252-210.
11. Hui KY, Hermann RB, Manetta JV, Gygi T, Angleton EL. 1993. Model peptides to study the effects of P2 and P3 substitutions in statine-containing HIV proteinase inhibitors. FEBS Lett 327:355-360.
12. Jones TA. 1985. Interactive computer graphics: FRODO. Methods Enzymol 115:157-171.
13. Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, Everitt L, Kempf DJ, Norbeck DW, Erickson JW, Swanstrom R. 1994. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci USA 91:5597-5601.
14. Kervinen J, Thanki N, Zdanov A, Tino J, Barrish J, Lin PF., Colonno R, Riccardi K, Samanta H, Wlodawer A. 1996. Structural analysis of the native and drug-resistant HIV-1 proteinases complexed with an aminodiol inhibitor. Protein Peptide Lett 3:399-406.
15. Laco GS, Schalk-Hihi C, Lubkowski J, Morris G, Zdanov A, Olson A, Elder JH, Wlodawer A, Gustchina A. 1997. Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor. Biochemistry 36:10696-10708.
16. Lange-Savage G, Berchtold H, Liesum A, Budt KH, Peyman A, Knolle J, Sedlacek J, Fabry M, Hilgenfeld R. 1997. Structure of HOE/BAY 793 complexed to human immunodeficiency virus (HIV-1) protease in two different crystal forms-structure/function relationship and influence of crystal packing. Eur J Biochem 248:313-322.
17. Lee T, Laco GS, Torbett BE, Fox HS, Lerner D, Elder JH, Wong C. 1998. Analysis of the S3 and S3′ subsite specificities of feline immunodeficiency virus (FIV) protease: Development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Proc Natl Acad Sci USA 95:939-944.
18. McCune JM. 1997. Animal models of HIV-1 disease. Science 278:2141-2142.
19. Mulichak AM, Hui JO, Tomasselli AG, Heinrikson RL, Curry KA, Tomich CS, Thaisrivongs S, Sawyer TK, Watenpaugh KD. 1993. The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. J Biol Chem 268:13103-13109.
20. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
21. Patick AK, Rose R, Greytok J, Bechtold CM, Hermsmeier MA, Chen PT, Barrish JC, Zahler R, Colonno RJ, Lin PF. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol 69:2148-2152.
22. Payne SL, Rausch J, Rushlow K, Montelaro RC, Issel C, Flaherty M, Perry S, Sellon D, Fuller F. 1998. Characterization of infectious molecular clones of equine infectious anaemia virus. J Gen Virol 75:425-429.
23. Powell DJ, Bur D, Wlodawer A, Gustchina A, Payne SL, Dunn BM, Kay J. 1996. Expression, characterisation and mutagenesis of the aspartic proteinase from equine infectious anaemia virus. Eur J Biochem 247:664-674. (Erratum. 1997. Eur J Biochem 246:258.
24. Ratner L, Fisher A, Jagodzinski LL, Mitsuya H, Liou RS, Gallo RC, Wong-Staal F. 1987. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses 3:57-69.
25. Roberts NA, Craig JC, Sheldon J. 1998. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice. AIDS 12:453-460.
26. Romines KR, Watenpaugh KD, Tomich PK, Howe WJ, Morris JK, Lovasz KD, Mulichak AM, Finzel BC, Lynn JC, Horng M, Schwende FJ, Ruwart MJ, Zipp GL, Chong K, Dolak LA, Toth LN, Howard GM, Rush BD, Wilkinson KF, Possen PL, Dalga RJ, Hinslaw RR. 1995. Use of medium-sized cycloalkyl rings to enhance secondary binding: Discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors. J Med Chem 38: 1884-1891.
27. Rose RB, Craik CS, Stroud RM. 1998. Domain flexibility in retroviral proteases: Structural implications for drug resistant mutations. Biochemistry 37:2607-2621.
28. Rosenberg N, Jolicoeur P. 1997. Retroviral pathogenesis. In: Coffin JM, Hughes SH, Varmus HE, eds, Retroviruses. New York: Cold Spring Harbor Laboratory Press. pp 475-585.
29. Satow Y, Cohen GH, Padlan EA, Davies DR. 1986. Phosphocholine binding immunoglobulin Fab McPC603: An X-ray diffraction study at 2.7 Å. J Mol Biol 190:593-604.
30. Schinazi RF, Larder BA, Mellors JW. 1997. Mutations in retroviral genes associated with drug resistance. Intl Antiviral News 5:129-142.
31. Slee DH, Laslo KL, Elder JH, Ollmann IR, Gustchina A, Kervinen J, Zdanov A, Wlodawer A, Wong C-H. 1995. Selectivity in the inhibition of HIV and FIV protease: Inhibitory and mechanistic studies of pyrrolidine-containing α-keto amide and hydroxyethylamine core structures. J Am Chem Soc 117:11867-11878.
32. Vandamme A, Van Vaerenbergh K, De Clercq E. 1998. Anti-human immunodeficiency virus drug combination strategies. Antivir Chem Chemother 9:187-203.
33. Willett BJ, Flynn JN, Hosie MJ. 1997. FIV infection of the domestic cat: An animal model for AIDS, Immunol Today 18-182-189.
34. Wilson SI, Phylip LH, Mills JS, Gulnik SV, Erickson JW, Dunn BM, Kay J. 1997. Escape mutants of HIV-1 proteinase: Enzymic efficiency and susceptibility to inhibition. Biochim Biophys Acta 1339:113-125.
35. Winslow DL, Stack S, King R, Scarnati H, Bincsik A, Otto MJ. 1995. Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res Hum Retroviruses 11:107-113.
36. Wlodawer A, Gustchina A, Reshetnikova L, Lubkowski J, Zdanov A, Hui KY, Angleton EL, Farmerie WG, Goodenow MM, Bhatt D, Zhang L, Dunn BM. 1995. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat Struct Biol 2:480-488.
37. Wlodawer A, Vondrasek J. 1998. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 27:249-284.
38. Wu J, Adomat JM, Ridky TW, Louis JM. Leis J, Harrison RW, Weber IT. 1998. Structural basis for specificity of retroviral proteases. Biochemistry 37:4518-4526.
39. Zhang L, Pennington MW, Baur P. Byrnes ME, De Chastonay J, Wilson SL, Kay J, Dunn BM. 1997. Binding of mutant HIV-1 proteases with junction B peptides containing methyleneamino isostere replacements. Protein Peptide Lett 4:225-235.